Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DDN001
MIFTS: 52

Duodenal Ulcer

Categories: Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Duodenal Ulcer

About this section

MalaCards integrated aliases for Duodenal Ulcer:

Name: Duodenal Ulcer 12 55 44 15 73
Stress Ulcer 12 55 73
Curling Ulcer 12 73
Stress Ulcer of Stomach 73
Duodenal Ulcer Disease 55
Curling's Ulcers 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Duodenal Ulcer

About this section
MalaCards based summary : Duodenal Ulcer, also known as stress ulcer, is related to duodenitis and gastroenteritis. An important gene associated with Duodenal Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Allograft rejection and Regulation of IFNA signaling. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon.

Sources

Related Diseases for Duodenal Ulcer

About this section

Diseases in the Duodenal Ulcer family:

Duodenal Ulcer Due to Antral G-Cell Hyperfunction

Diseases related to Duodenal Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 duodenitis 31.9 GAST INS
2 gastroenteritis 30.6 CXCL8 IL1B TNF
3 pancreatitis 30.5 CCK SCT SST
4 peritonitis 30.4 CXCL8 IL1B TNF
5 appendicitis 30.3 CXCL8 IL1B TNF
6 haemophilus influenzae 30.1 CXCL8 IL1B TNF
7 zollinger-ellison syndrome 30.1 GAST HRH2 SCT SST
8 neuroendocrine tumor 30.1 GAST GRP SST
9 lymphadenitis 30.1 CXCL8 IL1B TNF
10 intestinal disease 30.1 CXCL8 IL1B TNF
11 meningitis 30.0 CXCL8 IL1B TNF
12 periodontitis 30.0 CXCL8 IL1B TNF
13 esophagitis 29.9 CXCL8 CYP2C19 HRH2 IL1B
14 duodenogastric reflux 29.7 CCK GAST SCT SST
15 diarrhea 29.7 CCK GAST SST TNF
16 steatorrhea 29.6 CCK SCT SST
17 periodontal disease 29.6 CXCL8 IL1B IL1RN TNF
18 gastritis 29.5 CXCL8 GAST HRH2 IL1B IL1RN S100A8
19 islet cell tumor 29.4 GAST INS SST
20 peptic esophagitis 29.4 CXCL8 CYP2C19 HRH2 IL1B
21 acute pancreatitis 29.4 CCK CXCL8 SCT SST
22 burns 29.3 IL1B INS TNF
23 dyspepsia 29.1 CCK CXCL8 CYP2C19 HRH2 SST
24 insulinoma 29.0 INS SCT SST
25 atrophic gastritis 29.0 CXCL8 GAST IL1B IL1RN S100A8 SST
26 gastrinoma 29.0 GAST INS SCT SST
27 pancreatic cancer 28.9 CCK GAST GRP SCT SST
28 dumping syndrome 28.9 INS SCT SST
29 gastric ulcer 28.8 CXCL8 CYP2C19 GAST HRH2 IL1B IL1RN
30 duodenal gastrinoma 28.7 CCK GAST GRP SCT SST
31 arthritis 28.6 CXCL8 IL1B IL1RN LTA TNF
32 peptic ulcer disease 28.6 CXCL8 CYP2C19 GAST HRH2 IL1B IL1RN
33 helicobacter pylori infection 28.6 CXCL8 CYP2C19 GAST IL1B IL1RN S100A8
34 multiple endocrine neoplasia, type i 28.5 GAST INS SCT SST
35 gastroesophageal reflux 28.5 CCK CXCL8 CYP2C19 GAST HRH2 IL1B
36 pancreas disease 27.7 CCK INS SCT SST TNF
37 diabetes mellitus 27.4 IL1B IL1RN INS LTA SST TNF
38 tremor, nystagmus, and duodenal ulcer 12.2
39 duodenal ulcer due to antral g-cell hyperfunction 12.2
40 duodenal ulcer, hyperpepsinogenemic i 12.1
41 chronic erosive gastritis 11.2
42 neuhauser daly magnelli syndrome 11.1
43 xanthinuria, type ii 11.0
44 gastrointestinal neuroendocrine benign tumor 10.9 GAST SST
45 gastric neuroendocrine neoplasm 10.9 GAST SST
46 pylorospasm 10.9 GAST SST
47 systemic onset juvenile idiopathic arthritis 10.8 IL1B TNF
48 staphylococcal toxic shock syndrome 10.8 IL1B TNF
49 autoimmune myocarditis 10.8 IL1B TNF
50 kashin-beck disease 10.8 IL1B TNF

Graphical network of the top 20 diseases related to Duodenal Ulcer:



Diseases related to Duodenal Ulcer
Sources

Symptoms & Phenotypes for Duodenal Ulcer

About this section
Sources

Drugs & Therapeutics for Duodenal Ulcer

About this section

Drugs for Duodenal Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
2
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 2,Phase 3 443-48-1 4173
4
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
6
Pantoprazole Approved Phase 4,Phase 3,Phase 1,Not Applicable 102625-70-7 4679
7
Dexlansoprazole Approved, Investigational Phase 4,Phase 3 138530-94-6, 103577-45-3 9578005
8
Lansoprazole Approved, Investigational Phase 4,Phase 3 103577-45-3 3883
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
11
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3
12
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
13
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
14
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
15
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 1302 156391
16
Loxoprofen Approved, Investigational Phase 4 68767-14-6, 80382-23-6 3965
17
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
18
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
19
Furazolidone Approved, Investigational, Vet_approved Phase 4 67-45-8 3435 5323714
20
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 77-92-9 311
21 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
23 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
24 Antiparasitic Agents Phase 4,Phase 2,Phase 3
25 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
26 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antibiotics, Antitubercular Phase 4
42
Bismuth Phase 4,Phase 3 7440-69-9 16682734 105143
43 diuretics Phase 4,Phase 3,Phase 2
44 Expectorants Phase 4,Phase 3
45 Natriuretic Agents Phase 4,Phase 3,Phase 2
46 Respiratory System Agents Phase 4,Phase 3,Not Applicable
47 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3
48 Anticoagulants Phase 4
49 Renal Agents Phase 4
50 Ranitidine bismuth citrate Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Concomitant Therapy of H. Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers Completed NCT00594867 Phase 4 Acetaminophen - 4 grams per day + Placebo;Aspirin - 325 mg per day + Placebo;Acetaminophen 4 gram per day + Aspirin 325 mg per day
3 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
4 Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
5 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
6 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
7 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
8 Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment Completed NCT00534443 Phase 4
9 Argon Plasma Coagulation for Bleeding Peptic Ulcers Completed NCT02241044 Phase 4
10 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
11 Study Of Celecoxib In Healthy Subjects Completed NCT00994461 Phase 4 Celecoxib;Loxoprofen;Placebo
12 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
13 Helicobacter Eradication Aspirin Trial Active, not recruiting NCT01506986 Phase 4 Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg;Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
14 Lansoprazole Preventing Gastroduodenal Stress Ulcerations Terminated NCT00220909 Phase 4 Lansoprazole
15 Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
16 Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs Unknown status NCT02202967 Phase 3 Misoprostol;Placebo
17 Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
18 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
19 Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer Completed NCT01452724 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
20 Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
21 Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01452750 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
22 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
23 Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID Completed NCT00542789 Phase 3 Esomeprazole;Placebo
24 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Completed NCT01397448 Phase 2, Phase 3 E3810;E3810;Teprenone
25 Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
26 Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients Completed NCT02847455 Phase 2, Phase 3 5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
27 Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin Completed NCT01069939 Phase 3 Esomeprazole;Placebo
28 Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3) Completed NCT00952978 Phase 3 10 mg ilaprazole;20 mg omeprazole
29 Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
30 Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
31 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
32 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
33 Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer Completed NCT00595517 Phase 3 Esomeprazole 20 mg
34 Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA) Completed NCT00441727 Phase 3 Esomeprazole 40 mg;Esomeprazole 20 mg;Placebo
35 Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation Completed NCT01051388 Phase 3 Low-dose PPI (Rabeprazole sodium);High-dose PPI (Rabeprazole sodium);Non-PPI (Gefarnate)
36 ASTERIX: Low Dose ASA and Nexium Completed NCT00251966 Phase 3 Esomeprazole
37 Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment Completed NCT02084420 Phase 3 Ilaprazole;Pantoprazole
38 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
39 Ulcer Prevention II Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
40 Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
41 A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury Completed NCT01140828 Phase 3 Rabeprazole;Rabeprazole Placebo
42 Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori Completed NCT01505127 Phase 3 TAK-438;Lansoprazole;Amoxicillin;Clarithromycin
43 Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers Completed NCT00450658 Phase 3 HZT-501;Ibuprofen
44 Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment Completed NCT00450216 Phase 3 Ibuprofen/famotidine;Ibuprofen
45 Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Completed NCT00367211 Phase 3 PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Naproxen 500 mg tablets (PN 200 minus omeprazole)
46 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy Completed NCT00745459 Phase 3 NPO-11
47 A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00961350 Phase 3 PA32540;EC Aspirin 325
48 Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers Completed NCT00960869 Phase 3 PA32540;EC-Aspirin 325 mg
49 Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer Completed NCT00401752 Phase 3 Esomeprazole;Ranitidine
50 Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen Completed NCT01129011 Phase 3 PN400 (VIMOVO);Naproxen

Search NIH Clinical Center for Duodenal Ulcer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: duodenal ulcer

Sources

Genetic Tests for Duodenal Ulcer

About this section
Sources

Anatomical Context for Duodenal Ulcer

About this section

MalaCards organs/tissues related to Duodenal Ulcer:

41
Testes, Liver, Colon, Tonsil, Pancreas, Heart, Endothelial
Sources

Publications for Duodenal Ulcer

About this section

Articles related to Duodenal Ulcer:

(show top 50) (show all 871)
# Title Authors Year
1
Reply to the Letter by Dr. Antonio Ponzetto Regarding "The Role of History of Gastro-Duodenal Ulcer in Patients with Upper Gastrointestinal Bleeding". ( 29791893 )
2018
2
Laparoscopic omental filling with intraoperative endoscopy for a perforated duodenal ulcer. ( 29869066 )
2018
3
A rare complication of recurrent duodenal ulcer. ( 29549042 )
2018
4
Ten-Year Experience of Managing Giant Duodenal Ulcer Perforations with Triple Tube Ostomy at Tertiary Hospital of North India. ( 29581678 )
2018
5
Comparisons Between Bacterial Communities in Mucosa in Patients With Gastric Antrum Ulcer and a Duodenal Ulcer. ( 29868487 )
2018
6
Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. ( 29813089 )
2018
7
Management of a postbulbar duodenal ulcer and stricture causing gastric outlet obstruction: A case report. ( 29692890 )
2018
8
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. ( 29596646 )
2018
9
Duodenal Ulcer as a Postoperative Complication in the Donor in Living-Donor Liver Transplantation. ( 29731079 )
2018
10
Unusual Presentation of Duodenal Ulcer Presenting with Duodenal Intussusception. ( 29619400 )
2018
11
Phytobezoar and duodenal ulcer as complication of Duodopa therapy in a patient affected by Parkinson's disease. ( 29960957 )
2018
12
Containing the Costs of Recurrent Gastro-Duodenal Ulcer Bleeding. ( 29791892 )
2018
13
The Role of History of Gastro-Duodenal Ulcer in Patients with Upper Gastrointestinal Bleeding. ( 29342468 )
2018
14
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. ( 29889843 )
2018
15
<i>Gemella haemolysans</i> bacteremia in a patient with secondary peritonitis due to a duodenal ulcer perforation: A case report. ( 29942771 )
2018
16
Application of over-the-scope clip for massive duodenal ulcer bleeding in a 4-year-old boy weighing 7.8 kg. ( 29169193 )
2018
17
Feasibility of a novel laparoscopic technique with unidirectional knotless barbed sutures for the primary closure of duodenal ulcer perforation. ( 29470633 )
2018
18
Duodenal Ulcer - IgA Vasculitis. ( 28202872 )
2017
19
A case of an intractable duodenal ulcer associated with a pancreatic arteriovenous malformation. ( 28484196 )
2017
20
A Curious Case of Intestinal Diaphragm Disease Unmasked by Perforation of a Duodenal Ulcer. ( 28523070 )
2017
21
Perforated Duodenal Ulcer. ( 28248764 )
2017
22
Successful Endoscopic Treatment of Bouveret Syndrome in a Patient with Choledochoduodenal Fistula Complicating Duodenal Ulcer. ( 28758036 )
2017
23
Emphysematous pancreatitis associated with penetrating duodenal ulcer. ( 29358874 )
2017
24
The Relationship of Mean Platelet Volume/Platelet Distribution Width and Duodenal Ulcer Perforation. ( 28442518 )
2017
25
Endoscopic View of Gastroduodenal Artery Coils at the Base of Duodenal Ulcer in Case of Recurrent Massive Upper Gastrointestinal Bleed. ( 28507835 )
2017
26
Closure of duodenal ulcer perforation using a novel endoloop device with a single-channel gastroscope after failed laparoscopic repair. ( 28068696 )
2017
27
Massive Gastrointestinal Bleeding from Neonatal Duodenal Ulcer. ( 28975747 )
2017
28
Effectiveness of arterial embolization in recurrent bleeding due to duodenal ulcer during postoperative cardiac surgery. ( 28372451 )
2017
29
VacA and CagA Status as Biomarker of Two Opposite End Outcomes of Helicobacter pylori Infection (Gastric Cancer and Duodenal Ulcer) in a Moroccan Population. ( 28125638 )
2017
30
ExposAc: Different Faces of a Bleeding Giant Duodenal Ulcer. ( 28871345 )
2017
31
EVALUATION OF HUMAN LEUKOCYTE ANTIGEN CLASS I AND II ANTIGENS IN HELICOBACTER PYLORI-POSITIVE PEDIATRIC PATIENTS WITH ACTIVE GASTRITIS AND DUODENAL ULCER. ( 28977115 )
2017
32
Protein signature characterizing Helicobacter pylori strains of patients with autoimmune atrophic gastritis, duodenal ulcer and gastric cancer. ( 28465717 )
2017
33
Cytomegalovirus Associated Duodenal Ulcer and Duodenitis in a Malnourished Pediatric Patient. ( 29119032 )
2017
34
Declining prevalence of duodenal ulcer at endoscopy in Ile-Ife, Nigeria. ( 28875881 )
2017
35
A Rare Case of Pancreas Divisum Accompanied by Acute Pancreatitis Following Endoscopic Hemostasis for Duodenal Ulcer Bleeding. ( 28449428 )
2017
36
Adapted ERAS Pathway vs. Standard Care in Patients with Perforated Duodenal Ulcer-a Randomized Controlled Trial. ( 28653239 )
2017
37
Determination of <i>Helicobacter pylori</i> virulence-associated genes in duodenal ulcer and gastric biopsies. ( 29951396 )
2017
38
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. ( 27614656 )
2016
39
Successful Endoscopic Management of Non-Healing Perforated Duodenal Ulcer with Polyglycolic Acid Sheet and Fibrin Glue. ( 28119948 )
2016
40
A refractory duodenal ulcer with a biliary-duodenal fistula following the administration of bevacizumab. ( 27383109 )
2016
41
A life-threatening duodenal ulcer hemorrhage due to previously unknown primary hyperparathyroidism. ( 27616071 )
2016
42
PERFORATED DUODENAL ULCER ASSOCIATED WITH SITUS INVERSUS AND DEXTROCARDIA. ( 27323596 )
2016
43
Association of Endoscopic Esophageal Variceal Ligation with Duodenal Ulcer. ( 27097695 )
2016
44
Cytomegalovirus-infected duodenal ulcer with severe recurrent bleeding. ( 26852085 )
2016
45
Peritonitis Following Duodenal Ulcer Perforation in a Newborn: A Case Report. ( 28050434 )
2016
46
The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report. ( 27348901 )
2016
47
Pyopneumothorax and peritonitis due to perforated duodenal ulcer and associated pleuroperitoneal communication. ( 27372035 )
2016
48
The Effect of Helicobacter pylori Eradication on the Gastrointestinal Microbiota in Patients with Duodenal Ulcer. ( 27308643 )
2016
49
Successful Conservative Treatment of a Cholecystoduodenal Fistula Caused by a Cytomegalovirus-associated Duodenal Ulcer. ( 27629956 )
2016
50
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
Sources

Variations for Duodenal Ulcer

About this section
Sources

Expression for Duodenal Ulcer

About this section
Search GEO for disease gene expression data for Duodenal Ulcer.
Sources

Pathways for Duodenal Ulcer

About this section

Pathways related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 37
Show member pathways
 12.69 CXCL8 IL1B INS LTA TNF
2
Regulation of IFNA signaling 66
Show member pathways
 12.45 CXCL8 IL1B LTA TNF
3
IL-17 Family Signaling Pathways 65
Show member pathways
 12.09 CXCL8 IL1B S100A8 TNF
4
Spinal Cord Injury 1
11.87 CXCL8 IL1B TNF
5
IL-1 Family Signaling Pathways 65
Show member pathways
 11.87 CXCL8 IL1B IL1RN TNF
6
Interleukin-4 and 13 signaling 66
11.83 CXCL8 IL1B TNF
7
TNF signaling pathway 37
11.8 IL1B LTA TNF
8
Senescence and Autophagy in Cancer 1
11.79 CXCL8 IL1B INS
9
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.77 CXCL8 IL1B IL1RN SST TNF
10
AGE-RAGE signaling pathway in diabetic complications 37
11.75 CXCL8 IL1B TNF
11
Amoebiasis 37
11.73 CXCL8 IL1B TNF
12
Rheumatoid arthritis 37
11.67 CXCL8 IL1B TNF
13
Innate Lymphoid Cell Differentiation Pathways 65
11.6 IL1B LTA TNF
14
Pertussis 37
11.57 CXCL8 IL1B TNF
15
NF-kappa B signaling pathway 37
11.54 CXCL8 IL1B LTA TNF
16
Lung fibrosis 1
11.47 CXCL8 IL1B TNF
17
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 CXCL8 IL1B TNF
18
Legionellosis 37
11.35 CXCL8 IL1B TNF
19
Malaria 37
11.23 CXCL8 IL1B TNF
20
EBV LMP1 signaling 1
11.01 CXCL8 TNF
21
Cellular roles of Anthrax toxin 1
10.97 IL1B TNF
22
Interleukin-10 signaling 66
10.95 CXCL8 IL1B IL1RN TNF
23
Overview of nanoparticle effects 1
10.9 CXCL8 TNF
24
LDL Oxidation in Atherogenesis 64
10.81 IL1B TNF
25
Secretion of Hydrochloric Acid in Parietal Cells 1
10.1 GAST HRH2
26
Gastric acid production 1
9.77 CCK GAST GRP SCT
Sources

GO Terms for Duodenal Ulcer

About this section

Cellular components related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CCK CXCL8 GAST GRP IL1B IL1RN
2 extracellular space GO:0005615 9.4 CCK CXCL8 GAST GRP IL1B IL1RN
3 secretory granule lumen GO:0034774 9.33 GRP INS S100A8

Biological processes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.91 IL1B INS LTA SST
2 cytokine-mediated signaling pathway GO:0019221 9.91 CXCL8 IL1B IL1RN TNF
3 inflammatory response GO:0006954 9.88 CXCL8 IL1B IL1RN S100A8 TNF
4 response to lipopolysaccharide GO:0032496 9.83 CXCL8 IL1B LTA S100A8
5 activation of MAPK activity GO:0000187 9.8 IL1B INS TNF
6 immune response GO:0006955 9.8 CXCL8 HRH2 IL1B IL1RN LTA TNF
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 CCK S100A8 TNF
8 neutrophil chemotaxis GO:0030593 9.73 CXCL8 IL1B S100A8
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 IL1B INS S100A8 TNF
10 regulation of protein secretion GO:0050708 9.63 INS TNF
11 positive regulation of interferon-gamma production GO:0032729 9.63 IL1B LTA TNF
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IL1B TNF
13 negative regulation of growth of symbiont in host GO:0044130 9.62 LTA TNF
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL1B TNF
15 positive regulation of peptide hormone secretion GO:0090277 9.58 GRP INS
16 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IL1B TNF
17 regulation of establishment of endothelial barrier GO:1903140 9.57 IL1B TNF
18 G-protein coupled receptor signaling pathway GO:0007186 9.56 CCK CXCL8 GAST GRP HRH2 INS
19 positive regulation of fever generation GO:0031622 9.55 IL1B TNF
20 fever generation GO:0001660 9.54 IL1B IL1RN
21 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.51 LTA TNF
22 sequestering of triglyceride GO:0030730 9.49 IL1B TNF
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 IL1B TNF
24 embryonic digestive tract development GO:0048566 9.43 CXCL8 SCT TNF
25 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.37 LTA TNF
26 regulation of signaling receptor activity GO:0010469 9.36 CCK CXCL8 GAST GRP IL1B IL1RN
27 negative regulation of lipid catabolic process GO:0050995 9.33 IL1B INS TNF
28 signal transduction GO:0007165 10.18 CCK CXCL8 GAST GRP HRH2 IL1B

Molecular functions related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 CXCL8 IL1B IL1RN LTA TNF
2 interleukin-1 receptor binding GO:0005149 9.16 IL1B IL1RN
3 hormone activity GO:0005179 9.02 CCK GAST INS SCT SST
Sources

Sources for Duodenal Ulcer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....